Industry
AI Therapy Laws 2026: What PMHNPs Can Still Use AI For
Seven states now restrict AI in mental health care, and Illinois's law names psychiatric APRNs but not physicians. Here's what PMHNPs can still use AI for.
Read More →
TL;DR
- As of August 2026, no classic psychedelic is FDA-approved for any psychiatric indication, and psilocybin, MDMA, and LSD all remain Schedule I.
- On July 14, 2026, FDA published two psychedelic notices in the Federal Register on the same day: a final clinical trial guidance and a notice of a public hearing.
- Executive Order 14401, signed April 18, 2026, directs priority review vouchers, a Right to Try access pathway, and a rescheduling review after successful Phase 3 trials.
- State psilocybin programs in Oregon, Colorado, and New Mexico run on state permits, not prescriptions, and sit entirely outside insurance.
- The move that pays off this year is a prepared, accurate answer for patients who ask, not a new service line or a facilitator certificate.
What this guide covers
On July 14, 2026, the FDA published two separate psychedelic notices in the Federal Register on the same day. One finalized a clinical trial guidance that had been sitting in draft since June 2023. The other announced a public hearing on how these drugs might one day be delivered to patients.
Two notices, one morning, after three years of silence. That is not a coincidence, and it is the clearest signal yet that federal regulators are building the scaffolding for a decision.
Here is what has not changed. Nothing is approved. Nothing is prescribable. Every classic psychedelic is still Schedule I, which means a DEA registration does not authorize a single dose.
That gap between the headlines and the prescription pad is exactly where PMHNPs are getting caught. Patients are arriving with articles, podcast episodes, and travel plans. The clinician who can explain the real timeline in ninety seconds keeps the patient. The one who guesses loses credibility in both directions, whether by over-promising or by dismissing something that is genuinely moving.
Where Every Psychedelic Actually Stands
Start with the boring, load-bearing fact: as of August 2026 there is no FDA-approved classic psychedelic for any indication. Not psilocybin, not MDMA, not LSD, not ibogaine.
Psilocybin is the furthest along. Two Phase 3 trials of a synthetic psilocybin for treatment-resistant depression have reported meeting their primary endpoints, with results presented at the 2026 ASCP annual meeting and covered in detail by Psychiatric Times. The sponsor has said it expects to complete a rolling new drug application in the fourth quarter of 2026.
MDMA took the opposite path. Its application was rejected in August 2024, largely over trial design problems, and was resubmitted in 2026. A separate MDMA-related compound for PTSD is in development and received a national priority voucher. If you treat PTSD, that pipeline sits alongside the options in PTSD Treatment Updates for PMHNPs, not in place of them.
Ketamine is the exception that confuses everyone, and it is worth being precise about why. Ketamine is a Schedule III dissociative anesthetic, not a classic psychedelic. Racemic ketamine can be used off-label and esketamine carries an FDA approval with a REMS, which is why those services exist right now while psilocybin services do not. Ketamine and Esketamine in Psychiatric Practice walks through that distinction in clinical detail.
So when a patient with treatment-resistant depression asks what is available today, the honest answer still runs through approved and evidence-supported options, including the augmentation strategies covered in Pramipexole for Treatment-Resistant Depression.
The Two FDA Notices That Landed on One Day
The first July 14 notice announced the availability of a final guidance for industry, Psychedelic Drugs: Considerations for Clinical Investigations, filed under Docket No. FDA-2023-D-1987. It finalizes the draft FDA issued on June 26, 2023.
Its central problem is functional unblinding. When a participant knows within twenty minutes whether they received an active psychedelic or placebo, a trial can no longer separate the drug effect from the expectation effect. That is the flaw that sank the 2024 MDMA application, and the final guidance now tells sponsors how FDA expects them to handle it.
The second notice, Considerations for Potential Future Therapeutic Use of Psychedelic Drugs under Docket No. FDA-2026-N-7542, announced a public hearing on delivering these drugs in supervised and supportive settings. Read the framing carefully: that is a regulator asking how the treatment would be staffed and monitored, not whether the molecule works.
Both notices sit downstream of Executive Order 14401, signed April 18, 2026. As analyzed by Penn LDI, the order directs FDA to issue national priority vouchers to qualifying psychedelic compounds, instructs FDA and DEA to build a Right to Try access pathway including Schedule I handling authorizations, requires a rescheduling review for any Schedule I product that completes Phase 3 for a serious mental health disorder, and commits roughly $50 million to federal-state research with particular emphasis on ibogaine.
The voucher matters more than it sounds. It compresses a review that normally runs about ten months into a target of one to two months. That is the single biggest reason the timeline conversation changed this year.
State Programs Are Not a Federal Workaround
Three states now run regulated psilocybin access, and PMHNPs routinely misread what that means. A state program does not create a prescription. It creates a permitted, supervised administration setting that exists alongside federal Schedule I status, not instead of it.
Oregon has the longest track record and the most sobering numbers. More than 10,000 clients have gone through the program, with roughly 60% traveling from out of state, and about two dozen reported adverse events, none resulting in hospitalization. But as OPB reported in January 2026, about a third of licensed service centers have closed. Sessions running up to $3,000, annual licensing near $10,000, and insurance rates roughly triple those of comparable medical businesses produced fewer clients than the business models assumed.
Colorado runs a voter-approved natural medicine program with licensed healing centers and roughly 200 hours of facilitator training.
New Mexico is the one PMHNPs should actually watch, because it is the only medical-model program. Its Medical Psilocybin Act limits access to defined qualifying conditions, including treatment-resistant depression, PTSD, substance use disorder, and end-of-life anxiety and depression. Treatment follows a mandatory three-session structure: preparation, supervised administration in a Department of Health-approved setting, and integration. Clinicians must hold a New Mexico license plus a separate DOH permit specific to psilocybin services. The state has aimed to enroll first patients by the end of December 2026, with full implementation required by 2028.
None of this is billable to insurance. All of it is cash-pay, and none of it travels across state lines.
What to Say When a Patient Asks Today
Most PMHNPs will never administer a psychedelic. Nearly all of them will be asked about one, and that conversation is the actual clinical skill for 2026.
A workable three-part answer: name the real status, name the real timeline, and offer the real next step. “Nothing is approved yet, the closest one is psilocybin for treatment-resistant depression and it is still under review, and here is what we can do in the meantime.” Ninety seconds, no hedging, no eye-roll.
“The patients asking about psilocybin are not asking because they read a headline. They are asking because they have failed four medications and they are out of patience. If you dismiss the question, you have not protected them, you have just made sure they do their next experiment without telling you.”
— Lindsay Hill, DNP, PMHNP-BC
Screen before you reassure. Personal or first-degree family history of psychosis or bipolar I disorder is the clearest signal to counsel against unsupervised use. Serotonergic agents and lithium matter for interactions, and uncontrolled hypertension or significant cardiac disease changes the risk calculus.
Then document what you actually heard, without flinching. A patient who tells you about a retreat is handing you clinical data, and the goal is to stay the person they tell next time. If the conversation turns into a request you cannot fill, the script structure in Saying No to Controlled Substances transfers almost directly, and telehealth visits carry their own controlled substance constraints covered in DEA Telehealth Prescribing in 2026.
For the medications you can reach for while all of this plays out, our free prescribing cheat sheet covers dosing and monitoring across the categories most likely to come up in that same visit.
What Most People Get Wrong
The common assumption is that FDA approval is the finish line, and that clinicians who want in should get trained now so they are ready on day one.
Approval is not the finish line. It is the point at which the harder problem starts.
An approved psilocybin product would still need DEA rescheduling out of Schedule I before a single prescription could be written. It would almost certainly arrive with a REMS specifying who may administer it and where. There are currently no FDA-recognized facilitator training standards, no established CPT codes for a dosing session, and no national facility standards. A certificate bought in 2026 has no guaranteed relationship to whatever credential a future REMS actually names.
Oregon is the proof. Demand was never the constraint there, with more than 10,000 clients served. Delivery economics were, and a third of the service centers closed anyway. That is what happens when access arrives before a payment model does.
Notice what FDA asked about in its July hearing notice: supervised and supportive settings. Regulators are not stuck on whether the molecule works. They are working on the six to eight hours of clinician time per session that nobody has figured out how to staff or pay for.
The practical implication flips the usual advice. Do not buy a certificate this year. Build the conversation skill, keep your treatment-resistant depression pathway sharp, and watch New Mexico, because a medical-model state program will surface the credentialing and workflow questions long before a federal REMS does.
Frequently Asked Questions
Can a PMHNP legally prescribe psilocybin or MDMA in 2026?
No. Every classic psychedelic remains a Schedule I controlled substance, which means it has no accepted federal medical use and cannot be prescribed on a DEA registration. The only legal routes are an approved clinical trial, an expanded-access or Right to Try pathway, or a state-regulated program that operates under a separate state permit rather than a prescription.
Is ketamine a psychedelic, and does the same rule apply?
Ketamine is a Schedule III dissociative anesthetic, not a classic psychedelic, and it plays by completely different rules. Racemic ketamine can be used off-label, and esketamine is FDA-approved for treatment-resistant depression under a REMS program. This is why ketamine services exist today while psilocybin services do not.
When will psilocybin actually be FDA-approved?
No approval date exists yet. Two Phase 3 trials of a synthetic psilocybin for treatment-resistant depression have reported meeting their primary endpoints, and the sponsor has said it expects to complete its rolling submission in late 2026. Even with a priority voucher shortening review, approval would then be followed by DEA rescheduling and REMS build-out before any patient could be treated.
Should I get psychedelic facilitator training now?
For most PMHNPs, not yet. There are no FDA-recognized training standards, no CPT codes, and no facility standards, so a certificate purchased in 2026 may not map to whatever credential a future REMS requires. The exception is a clinician who intends to work inside a specific state program and can read that state’s actual permit requirements.
What do I document when a patient tells me they used psilocybin on their own?
Document it the way you document any substance use: what, how much, how often, the setting, and the effect on their symptoms and function. Screen for the interactions that matter, especially serotonergic agents and lithium, and reassess psychosis and bipolar risk. Non-judgmental documentation keeps the patient talking, which is the only way you learn about the next episode.
Do state psilocybin programs let me bill insurance?
No. State programs operate outside the federal reimbursement system entirely, so sessions are cash-pay. In Oregon, sessions have run as high as roughly $3,000, which is a major reason the program’s economics have been difficult for service centers.
The Bottom Line
Two Federal Register notices on one July morning told you that the federal government is building infrastructure, not just watching trials. That is real movement. It is also not a prescription, and it will not be one this year.
The PMHNPs who handle this well in 2026 will not be the ones with a certificate. They will be the ones who can answer the question accurately in ninety seconds, screen for the contraindications that matter, and keep a patient talking about what they are actually doing.
One concrete next step this week: write your ninety-second answer down, say it out loud twice, and put it in the same place you keep your other hard-conversation scripts. The next patient who asks will not schedule it in advance.
Stop guessing on the hard questions
The Psych NP Fellowship is a 12-month clinical mentorship for new and early-career PMHNPs, with live coaching, real case consultation, and 75 ANCC contact hours built in.
This content is for educational purposes and does not replace individualized clinical judgment or supervision.
About the author
Lindsay Hill, DNP, PMHNP-BC is the founder of the Psych NP Fellowship, a 12-month clinical mentorship program for new and early-career psychiatric nurse practitioners. She is a published contributor to Psychiatric Times, past President of the Arizona APNA Chapter, and co-founder of the Psych NP Network.
